213 related articles for article (PubMed ID: 8831730)
1. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
2. CPT-11 converting enzyme from rat serum: purification and some properties.
Tsuji T; Kaneda N; Kado K; Yokokura T; Yoshimoto T; Tsuru D
J Pharmacobiodyn; 1991 Jun; 14(6):341-9. PubMed ID: 1783980
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
4. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
5. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
[TBL] [Abstract][Full Text] [Related]
6. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
7. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
10. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
11. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
12. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
13. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
15. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
16. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Danks MK; Morton CL; Pawlik CA; Potter PM
Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
20. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
